

COLON  
DISEASE ORIENTED GROUP  
AGENDA

**OPEN SESSION**

VENUE: ROSSETTI ROOM, CHELSEA HOTEL, TORONTO

DATE SATURDAY, APRIL 29th, 2017

TIME: 10:30 – 12:00

**CHAIRS: DR. DEREK JONKER & DR. SHARLENE GILL**

---

- 10:30 WELCOME AND INTRODUCTION **DR. D. JONKER / DR. S. GILL**
- 10:30 UPDATES FROM FINAL ANALYSES  
**CO.23:** A PHASE III RANDOMIZED STUDY OF BBI608 AND BEST SUPPORTIVE CARE VERSUS PLACEBO AND BEST SUPPORTIVE CARE IN PATIENTS WITH PRETREATED ADVANCED COLORECTAL CARCINOMA **DR. D. JONKER**
- 10:40 ACTIVE/RECENTLY CLOSED TRIALS FOR UPDATE  
**CO.26:** A PHASE II/III TRIAL OF DURVALUMAB AND TREMELIMUMAB AND BEST SUPPORTIVE CARE VS BEST SUPPORTIVE CARE ALONE IN PATIENTS WITH ADVANCED COLORECTAL ADENOCARCINOMA REFRACTORY TO STANDARD THERAPIES **DR. H. KENNECKE (DR. E. CHEN)**
- CO.21 (CHALLENGE):** A PHASE III STUDY OF THE IMPACT OF A PHYSICAL ACTIVITY PROGRAM ON DISEASE-FREE SURVIVAL IN PATIENTS WITH EARLY STAGE COLON CANCER: A RANDOMIZED CONTROLLED TRIAL (CHALLENGE) **DR. C. BOOTH**
- 10:55 APPROVED TRIALS IN DEVELOPMENT  
**CO.25 (FOCUS 4):** MOLECULARLY STRATIFIED RCT PROGRAMME FOR SELECTION OF THERAPY IN METASTATIC CRC POST INDUCTION 1ST LINE TREATMENT **DR. R. GOODWIN**
- CO.27 (IROCAS):** - IRINOTECAN AND OXALIPLATIN FOR COLON CANCER IN THE ADJUVANT SETTING: MFOLFIRINOX TRIPLET CHEMOTHERAPY FOR HIGH-RISK STAGE III COLON CANCER IN ADJUVANT SETTING (IROCAS STUDY): A PHASE III RANDOMISED TRIAL **DR. S. GILL**

COLON  
DISEASE ORIENTED GROUP  
AGENDA

**OPEN SESSION**

VENUE: ROSSETTI ROOM, CHELSEA HOTEL, TORONTO

DATE SATURDAY, APRIL 29th, 2017

TIME: 10:30 – 12:00

**CHAIRS: DR. DEREK JONKER & DR. SHARLENE GILL**

---

11:20 NEW CONCEPTS IN DEVELOPMENT

**AGITG MONARCC:** A RANDOMISED PHASE 2 STUDY OF PANITUMUMAB MONOTHERAPY AND PANITUMUMAB PLUS 5 FLUOROURACIL AS FIRST LINE THERAPY FOR RAS AND BRAF WILD TYPE METASTATIC COLORECTAL CANCER **DR. D. JONKER**

11:35 INTERGROUP TASK FORCE UPDATE

**CR1643:** PHASE II STUDY OF CIRCULATING TUMOR DNA (CTDNA) AS A PREDICTIVE MARKER FOR RESPONSE TO ADJUVANT CHEMOTHERAPY IN PATIENTS WITH STAGE II COLON CANCER **DR. S. GILL**

**NRG CR1556 (COMMIT):** A RANDOMIZED PHASE III STUDY OF MFOLFOX6/BEVACIZUMAB COMBINATION CHEMOTHERAPY WITH OR WITHOUT ATEZOLIZUMAB OR ATEZOLIZUMAB MONOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH MICROSATELLITE INSTABILITY-HIGH (MSI-H) METASTATIC COLORECTAL CANCER **DR. D. JONKER**

**ALLIANCE A021502:** RANDOMIZED PHASE III STUDY OF MFOLFOX6 X 6 MONTHS WITH OR WITHOUT ATEZOLIZUMAB X 12 MONTHS IN THE ADJUVANT TREATMENT OF PATIENTS WITH MSI-H RESECTED STAGE 3 COLON CANCER **DR. S. GILL**

**SWOG 1613:** RANDOMIZED PHASE 2 STUDY IN HER2 AMPLIFIED MCRC AFTER FAILURE OF FIRST-LINE THERAPY **DR. S. GILL**

12:00 CLOSING REMARKS